Answers are grounded in this paper and cite their sources.
Forward chemical genetic screening is analogous to the classical genetics strategy of mutagenesis, except that a small molecule takes the place of a genetic mutation in altering the function of one or more gene products. In their Perspective, [Bellows and Tyers][1] discuss an elegant forward chemical genetic screen that identifies small-molecule inhibitors called ubistatins that disrupt the cell's protein degradation machinery ([ Verma et al .][2]). This work is an excellent example of the systematic identification of small-molecule inhibitors of complex biological processes and the characterization of their molecular targets. [1]: http://www.sciencemag.org/cgi/content/full/306/5693/67 [2]: http://www.sciencemag.org/cgi/content/short/306/5693/117
No takes yet. Share an insight, caveat, or question.
Bellows et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: